Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis

por Velásquez, Gustavo E., Brooks, Meredith B., Coit, Julia M., Sánchez Garavito, Epifanio, Calderón, Roger I., Jiménez, Judith, Tintaya, Karen, Peloquin, Charles A., Osso, Elna, Lecca, Leonid, Davies, Geraint R., Mitnick, Carole D.
Publicado 2019

Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis

por Tupasi, Thelma, Gupta, Rajesh, Danilovits, Manfred, Cirule, Andra, Sanchez-Garavito, Epifanio, Xiao, Heping, Cabrera-Rivero, Jose L, Vargas-Vasquez, Dante E, Gao, Mengqiu, Awad, Mohamed, Gentry, Leesa M, Geiter, Lawrence J, Wells, Charles D
Publicado 2016

Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial

por Milstein, Meredith, Lecca, Leonid, Peloquin, Charles, Mitchison, Denis, Seung, Kwonjune, Pagano, Marcello, Coleman, David, Osso, Elna, Coit, Julia, Vargas Vasquez, Dante Elmo, Sanchez Garavito, Epifanio, Calderon, Roger, Contreras, Carmen, Davies, Geraint, Mitnick, Carole D.
Publicado 2016